In vitro activity of non-bactericidal concentrations of polymyxin B in combination with other antimicrobials against OXA-23-producing carbapenem-resistant Acinetobacter baumannii

Netto, Bárbara Helena Teixeira; Vieira, Bruno; Hermes, Djuli Milene; Ribeiro, Vanessa Bley; Zavascki, Alexandre Prehn

doi:10.1016/j.bjid.2013.02.002

Cited by 6 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As only one study was conducted on the meropenem-susceptible strains, subgroup analysis was not performed for this combination therapy. 16 , 17 , 20 , 27 , 34 , 48 , 50 , 57 , 59 , 60 …”

Section: Resultsmentioning

confidence: 99%

Synergy effect of meropenem-based combinations against <em>Acinetobacter baumannii</em>: a systematic review and meta-analysis

Jiang

2018

IDR

View full text Add to dashboard Cite

PurposeThe main objective of our meta-analysis was to examine the in vitro synergistic effect of meropenem-based combination therapies against Acinetobacter baumannii through a systematic review of the existing literature.MethodsAn extensive search was performed with no restrictions on date of publication, language, and publication type. Our study evaluated the main conclusions drawn from various studies describing the synergistic activity of combination therapies in vitro.ResultsIn this review, 56 published studies were included. Our report included data on 20 types of antibiotics combined with meropenem in 1,228 Acinetobacter baumannii isolates. In time-kill studies, meropenem combined with polymyxin B and rifampicin showed synergy rates of 98.3% (95% CI, 83.7%–100.0%) and 89.4% (95% CI, 57.2%–100.0%), respectively, for Acinetobacter baumannii, modest synergy rates were found for meropenem combined with several antibiotics such as colistin and sulbactam, and no synergy effect was displayed in the combination of meropenem and ciprofloxacin, whereas in checkerboard method, the synergy rates of polymyxin B and rifampicin were 37.0% (95% CI, 0.00%–100.0%) and 56.3% (95% CI, 8.7%–97.8%), respectively.ConclusionWe found that time-kill studies generally identified the greatest synergy, while checkerboard and Etest methods yielded relatively poor synergy rates. Further well-designed in vivo studies should be carried out to confirm these findings.

show abstract

“…As only one study was conducted on the meropenem-susceptible strains, subgroup analysis was not performed for this combination therapy. 16 , 17 , 20 , 27 , 34 , 48 , 50 , 57 , 59 , 60 …”

Section: Resultsmentioning

confidence: 99%

Synergy effect of meropenem-based combinations against <em>Acinetobacter baumannii</em>: a systematic review and meta-analysis

Jiang

2018

IDR

View full text Add to dashboard Cite

show abstract

“…Gram-negative peritonitis is particularly troublesome and severe resulting mostly in technique failure, catheter removal or even lethal out- come 5,6 . The increased incidence of multiresistant strains of Acinetobacter has been reported in Serbia as well as in Italy, Greece, Slovakia, China and USA 16,17 . Multiple myeloma is a disease characterised by a high incidence of severe complications, especially when renal function is disturbed and patients are subjected to any of dialysis methods (HD or PD) 7,8 .…”

Section: Discussionmentioning

confidence: 99%

An experience with colistin applied in treatment of imunocompromised patients with peritonitis on peritoneal dialysis

Gvozdenović

Majstorović-Strazmester

et al. 2015

VOJNOSANIT PREGL

View full text Add to dashboard Cite

Introduction.Immunocompromised patients, such as those with multiple myeloma on peritoneal dialysis, are particularly susceptible to the occurrence of peritonitis. Case report. We presented a 56-year-old female patient with a 10-year history of multiple myeloma. The patient was on peritoneal dialysis since 2010. During 2012 the patient had the first episode of peritonitis that was successfully managed, but in 2013 the second episode of peritonitis occured. Analysis of dialysate culture and exit site swab revealed the presence of multiresistant Acinetobacter spp., which was susceptible only to colistin. Prompt colistin therapy was administered at the doses of 100,000 units/day during six days, which resulted in complete recovery of the patient, as well as improvement of local abdominal findings. Gram-negative bacteria (genus Acinetobacter) are common causative agents in hospital-acquired infections. Studies confirmed susceptibility of Acinetobacter to colistin, which was also the case with the presented patient. Intravenous administration of colistin resulted in a complete remission of this severe, life-threatening peritonitis. Conclusion. Patients with multiple myeloma and renal failure are highly prone to severe life-threatening infections.Uvod. Imunokompromitovani bolesnici, kao što su bolesnici sa multiplim mijelomom na peritoneumskoj dijalizi, posebno su skoloni nastanku peritonitisa. Prikaz bolesnika. Prikazali smo bolesnicu, staru 56 godina, koja je bolovala od multiplog mijeloma 10 godina. Od 2010. god. lečila se metodom peritoneumske dijalize. Prvu epizodu peritonitisa koja je uspešno sanirana, imala je tokom 2012. U 2013. ponovo je došlo do razvoja peritonitisa. Analizom kulture dijalizata i brisom izlaznog mesta peritoneumskog katetera izolovan je multirezistentni Acinetrobacter spp, osetljiv samo na kolistin. Primenom kolistina u dozi od 100 000 jedinica/dan tokom šest dana došlo je do potpunog poboljšanja opšteg stanja bolesnice, kao i lokalnog nalaza na trbuhu. Gramnegativna bakterija (Acinetobacter spp) čest je uzročnik hospitalnih infekcija. Istraživanja potvrđuju osetljivost Acinetobacter spp. na kolistin, što je slučaj kod prikazane bolesnice. Intravenska primena kolistina rezultovala je potpunim oporavkom od teškog, po život opasnog, peritonitisa. Zaključak. Bolesnici sa multiplim mijelomom i bubrežnom insuficijencijom imaju povećanu sklonost ka nastanku teških, po život opasnih, infekcija.

show abstract

In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: A systematic review and meta-analysis

Shao

et al. 2015

International Journal of Antimicrobial Agents

108

View full text Add to dashboard Cite

In vitro activity of non-bactericidal concentrations of polymyxin B in combination with other antimicrobials against OXA-23-producing carbapenem-resistant Acinetobacter baumannii

Cited by 6 publications

References 4 publications

Synergy effect of meropenem-based combinations against <em>Acinetobacter baumannii</em>: a systematic review and meta-analysis

Synergy effect of meropenem-based combinations against <em>Acinetobacter baumannii</em>: a systematic review and meta-analysis

An experience with colistin applied in treatment of imunocompromised patients with peritonitis on peritoneal dialysis

In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: A systematic review and meta-analysis

Contact Info

Product

Resources

About